- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05037279
Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)
A Multicenter, Randomized, Double-blind, Controlled Phase III Non-inferiority Study Assessing Efficacy and Safety of VERITY-BCG in Management of Intermediate and High-risk Non-muscle Invasive Bladder Cancer (NMIBC) in BCG-naïve Patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study is a randomized, active control, double-blind clinical trial aimed at demonstrating non - inferiority of VERITY-BCG to OncoTICE, the current standard of care, with respect to two-year Recurrence Free Survival (RFS) rates in NMIBC BCG - naïve patients that are at high risk for recurrence (defined as >50%).
• Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT.
Study Type
Enrollment (Anticipated)
Phase
- Phase 3
Contacts and Locations
Study Contact
- Name: Jalees Farhan
- Phone Number: 1-800-977-9778
- Email: medinfo@veritypharma.com
Study Contact Backup
- Name: Taniya Mann
- Phone Number: 1-800-977-9778
- Email: medinfo@veritypharma.com
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male or Female
- 18 years and older
- Low or high-grade NMIBC as defined by 2004 World Health Organization (WHO)/International Society of Urological Pathology (ISUP) classification and Grade 2 or 3 in the 1973 classification, diagnosed within 60 days of registration.
Pathologically confirmed and completely resected stage Ta or T1 urothelial cell carcinoma, with or without associated carcinoma in situ (CIS), diagnosed within 60 days of registration.
- Patients with T1 disease must have imaging demonstrating no evidence of metastatic disease (based on MRI or CT scan) within 90 days of registration, to confirm stage T1N0M0 disease.
- For patients with stage T1 disease, repeat TURBT must be performed as per standard of care/CUA guidelines.
- Patients may have intermediate or high recurrence risk disease, as indicated by the probability of 2-year recurrence of ≥ 50% based on the EORTC Bladder Cancer risk calculator.
- ECOG performance status of 0-2
Adequate organ and marrow function as defined below:
- leukocytes ≥3,000/mcL
- absolute neutrophil count ≥1,500/mcL
- platelets ≥100,000/mcL
- total bilirubin ≤ 1.5 × institutional upper limit of normal (ULN)
- AST(SGOT)/ALT(SGPT) ≤3 × institutional ULN
- creatinine ≤ institutional ULN OR glomerular filtration rate (GFR) ≥50 mL/min/1.73 m2 unless data exists supporting safe use of BCG at lower kidney function values, no lower than 30 mL/min/1.73 m2
- For women of childbearing potential involved in any sexual intercourse that could lead to pregnancy: Negative pregnancy test and willingness to use contraceptive (consistent with local regulations) during 120 days after the last dose of the study treatment. Note: The use of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile-vaginal intercourse 120 days after last dose of study drug treatment. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the participant.
Note: A woman of non-childbearing potential is defined as follows:
- Has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy);
- Has had a cessation of menses for at least 12 months without an alternative medical cause, and a follicle-stimulating hormone (FSH) test confirming nonchildbearing potential (refer to laboratory reference ranges for confirmatory levels).
- Male patients with female partner of childbearing potential must agree to be abstinent or practice an effective method of contraception.
Male patients must agree to refrain from donating sperm during the treatment period and for at least 120 days after the last dose of study treatment.
Exclusion Criteria:
- Presence of urothelial carcinoma involving the upper urinary tract or prostatic urethra documented by radiological imaging or biopsy, performed within 12 months of the start of treatment. Should the imaging or biopsy be performed outside the window it will be up to the physicians' discretion to re-scan/biopsy. This is considered T4 disease.
- CIS only disease.
- Pure squamous cell carcinoma or adenocarcinoma.
- Presence of micropapillary components.
Other prior non-bladder malignancy, except for the following:
- adequately treated basal cell or squamous cell skin cancer.
- in situ cervical cancer.
- adequately treated stage I or II cancer currently in complete remission, or any other cancer from which the patient has been disease free for five years.
- patients with localized prostate cancer who are being followed by an active surveillance program are also eligible.
- Prior intravesical BCG or intradermal BCG, with the exception of tuberculosis vaccination in childhood.
- Chronic administration of steroids (>10 mg prednisone) at the time of randomization.
- Current or planned concomitant biologic therapy, radiation therapy, hormonal therapy, chemotherapy, surgery, or other cancer therapy while on study.
- Prior chemoradiation treatment (trimodal therapy or "TMT") for bladder cancer.
- Currently being treated or scheduled to have treatment with any systemic or intravesical chemotherapeutic agent during the study.
- Receiving any other investigational agents.
- The presence of an impaired immune response irrespective of whether this impairment is congenital or caused by disease, drugs or other therapy.
- Known positive HIV serology.
- Presence of a urinary tract infection; treatment should be withheld until urine culture is negative and antibiotic therapy is stopped.
- Trauma to the urinary bladder. In case of gross hematuria, therapy should be stopped or postponed until the hematuria has been successfully treated or has resolved.
- History of allergic reactions attributed to compounds of similar chemical or biologic composition to BCG vaccine.
- Uncontrolled intercurrent illness.
- Psychiatric illness/social situations that would limit compliance with study requirements.
- Pregnancy: pregnant women are excluded from this study because VERITY-BCG is an agent with the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with VERITY-BCG, breastfeeding should be discontinued if the mother is treated with VERITY-BCG.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Verity-BCG
|
Other Names:
|
Active Comparator: OncoTICE
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence Free Survival (RFS) at 24 months
Time Frame: 24 months
|
Cumulative Recurrence Free Survival (RFS) at 24 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function. Recurrence will be defined as the reappearance of any of the NMIBC tumors as confirmed by cystoscopic biopsy or TURBT. |
24 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence Free Survival (RFS)
Time Frame: 36 months
|
Cumulative Recurrence Free Survival (RFS) at 36 months following 1st intravesical instillation as estimated using the Kaplan - Meier estimator of the survival function.
|
36 months
|
Progression Free Survival (PFS)
Time Frame: 24 months
|
Progression Free Survival (PFS) at 24 months as estimated using the Kaplan - Meier estimator of the survival function.
|
24 months
|
Progression Free Survival (PFS)
Time Frame: 36 months
|
Progression Free Survival (PFS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function.
|
36 months
|
Overall Survival (OS)
Time Frame: 36 months
|
Overall Survival (OS) at 36 months as estimated using the Kaplan - Meier estimator of the survival function.
|
36 months
|
Change in Quality of Life
Time Frame: 36 months
|
Change in Quality of Life as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for NMIBC (EORTC-QLQ-NMIBC24) over 36 months. The EORTC QLQ-NMIBC24 is a 24-item self-administered questionnaire that measures health-related quality of life in patients with intermediate to high-risk NMIBC. Items are ranked by the patient from 1 to 4 indicating the extent to which they have experienced those symptoms or problems. 1 = Not at All, 2 = A little, 3=Quite a bit, 4 = Very Much. - High Score is equivalent to more problems, except for items on sexual function and sexual enjoyment for which a high score is interpreted as better function. |
36 months
|
Change in functioning and symptom status
Time Frame: 36 months
|
Change in functioning and symptom status as measured by the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life questionnaire for Cancer Patients (EORTC-QLQ-C30) over 36 months. The EORTC QLQ-C30 consists of 30 items and measures Health Related Quality of Life as well as presence of symptoms across all cancer types. The QLQ-C30 includes nine multi-item scales:
High score = More symptoms or worse problems *High Score = Better overall health or Quality of life. |
36 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety: Incidence of treatment-emergent AEs and SAEs
Time Frame: 36 months
|
Incidence of treatment-emergent AEs and SAEs defined according to the CTCAE v5.0;
|
36 months
|
Safety: Number of discontinued subjects
Time Frame: 36
|
Number of subjects discontinuing study drug due to AEs
|
36
|
Safety: concomitant medications
Time Frame: 36 months
|
Usage of concomitant medications over time.
|
36 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Alexandre R Zlotta, MD, Princess Margaret Cancer Centre, 610 University Ave Toronto, ON, M5G 2M9, Canada
- Principal Investigator: Girish S Kulkarni, MD, Princess Margaret Cancer Centre, 700 University Ave, 6-824 Toronto, ON, M5G 1X6, Canada
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Neoplasms by Histologic Type
- Neoplasms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Neoplasms, Glandular and Epithelial
- Urinary Bladder Diseases
- Disease Attributes
- Carcinoma
- Recurrence
- Urinary Bladder Neoplasms
- Carcinoma, Transitional Cell
- Physiological Effects of Drugs
- Immunologic Factors
- Adjuvants, Immunologic
- BCG Vaccine
Other Study ID Numbers
- VRT-BCG-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Bladder Cancer
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedStage III Bladder Cancer | No Evidence of Disease | Stage II Bladder Cancer | Stage IVA Bladder Cancer | Stage IVB Bladder CancerUnited States
-
H. Lee Moffitt Cancer Center and Research InstituteCompletedMuscle-Invasive Bladder Carcinoma | Bladder Cancer Stage II | Bladder Cancer Stage III | Bladder Cancer Stage IVUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)WithdrawnRecurrent Bladder Cancer | Urinary Complications | Stage 0 Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder Cancer
-
National Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
National Cancer Institute (NCI)TerminatedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Bladder Adenocarcinoma | Bladder Squamous Cell Carcinoma | Bladder Urothelial Carcinoma | Stage I Bladder Cancer | Stage II Bladder CancerUnited States
-
Fox Chase Cancer CenterTerminatedStage III Bladder Cancer | Distal Urethral Cancer | Proximal Urethral Cancer | Squamous Cell Carcinoma of the Bladder | Urethral Cancer Associated With Invasive Bladder Cancer | Stage II Bladder CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedStage III Bladder Cancer | Stage IV Bladder Cancer | Recurrent Bladder Carcinoma | Stage II Bladder CancerUnited States
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Bristol-Myers SquibbRecruitingUrinary Bladder Cancer | Invasive Bladder CancerNetherlands
-
Taris Biomedical LLCBristol-Myers SquibbTerminatedBladder Cancer TNM Staging Primary Tumor (T) T2 | Bladder Cancer TNM Staging Primary Tumor (T) T2A | Bladder Cancer TNM Staging Primary Tumor (T) T2B | Bladder Cancer TNM Staging Primary Tumor (T) T3 | Bladder Cancer TNM Staging Primary Tumor (T) T3A | Bladder Cancer TNM Staging Primary Tumor... and other conditionsUnited States
-
Baylor College of MedicinePfizerTerminatedBladder Cancer | Invasive Bladder Cancer | Metastatic Bladder CancerUnited States
Clinical Trials on Bacillus Calmette-Guerin: Strain Russian BCG-I
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI)Active, not recruitingStage 0is Bladder Urothelial Carcinoma | Stage I Bladder Urothelial Carcinoma | Stage 0 Bladder Urothelial CarcinomaUnited States
-
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.Air Force Military Medical University, China; Jiangsu Province Centers for... and other collaboratorsCompleted
-
Cadila PharnmaceuticalsCompleted
-
Murdoch Childrens Research InstituteBill and Melinda Gates Foundation; Royal Children's HospitalCompletedCOVID-19 | Corona Virus Infection | Coronavirus Disease 2019 (COVID-19) | Respiratory IllnessAustralia, Brazil, Netherlands, Spain, United Kingdom
-
Mindful Diagnostics and Therapeutics, LLCCompleted
-
Massachusetts General HospitalCompleted
-
Murdoch Childrens Research InstituteRoyal Children's Hospital; Mercy Hospital for Women, AustraliaCompleted
-
Mansoura UniversityRecruitingNon-Muscle Invasive Bladder CancerEgypt
-
ImmunityBio, Inc.Active, not recruitingNon Muscle Invasive Bladder CancerUnited States
-
Steven E Arnold, MDActive, not recruitingAlzheimer Disease | Mild Cognitive Impairment | Mild Dementia | Moderate DementiaUnited States